Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report)’s stock price fell 5.7% during mid-day trading on Thursday . The stock traded as low as $11.85 and last traded at $11.85. 170 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 14,562 shares. The stock had previously closed at $12.57.
Analyst Ratings Changes
Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of “Hold”.
Get Our Latest Report on SNPHY
Santen Pharmaceutical Stock Down 1.1%
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Read More
- Five stocks we like better than Santen Pharmaceutical
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
- IREN Is Flipping the Switch from Bitcoin to AI
- This Quantum Computing Stock May Be Closer to a Breakout Than You Think
- RTX Is Set to Revolutionize Munitions Manufacturing
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
